Archive

ISH/BSH 2016: Advances in our understanding of clonal evolution in MM: where are we now?

Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA. by Maria Dalby: The dramatic improvement in MM survival in the last 40 years is largely linked to the introduction… read more.

ISH/BSH 2016: Professor Keith Stewart (Mayo Clinic, USA) discusses his presentation from the presidential session on genomic sequencing in this video. Also included article entitled ‘Genome-guided therapy in multiple myeloma’

Genome-guided therapy in multiple myeloma by Maria Dalby Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA Genomic sequencing of newly-diagnosed and refractory MM patients shows that combination therapy… read more.

ISH/BSH 2016: Professor Graham Jackson (Newcastle-Upon-Tyne, UK) discusses the risk factors and patient characteristics that most inform treatment selection for patients with R/R MM. Also included article ‘Risk stratification in the older patient: what are our priorities?’

Risk stratification in the older patient: what are our priorities? by Maria Dalby Professor Sonja Zweegman, VU University Medical Centre, Amsterdam, NL Biological age and frailty, rather than… read more.

ISH/BSH 2016: Professor Graham Jackson (Newcastle-Upon-Tyne, UK) discusses the risk factors and patient characteristics that most inform treatment selection for patients with R/R MM. Also included article 'Risk stratification in the older patient: what are our priorities?'

Risk stratification in the older patient: what are our priorities? by Maria Dalby Professor Sonja Zweegman, VU University Medical Centre, Amsterdam, NL Biological age and frailty, rather than… read more.

ISH / BSH 2016: A well attended joint ISH / BSH meeting in Glasgow brought together cutting edge research from both the UK and international myeloma community, whilst allowing lively debate on how best to implement recent advances within the environment of the NHS. Professor Paul G. Richardson (Boston, USA) and Professor Graham Jackson (Newcastle-Upon-Tyne, UK) give an international and British perspective on highlights from the meeting.

Green light for new medicines

by Gary Finnegan: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of seven new medicines, including one advanced therapy medicinal product (ATMP), at… read more.

EMA Highlights: Green light for new medicines

by Gary Finnegan: Six new medicines, two of which had been fast-tracked, were given positive reviews from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)…. read more.

ASH 2015: Building good combinations. Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) discusses the benefits of building good combinations early on in therapy and the impact that newly available triplet oral therapy will have on patients with myeloma

ASH 2015: Good news for patients from ASH! Erik Low (Chief Executive Myeloma UK), Professor Antonio Palumbo (University of Torino, Italy), Professor Paul Richardson (Harvard Medical School, Boston, USA) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA) discuss the things they will take home to their myeloma patients folloing ASH 2015

ASH 2015: Video Interview by Esther Drain. CDF changes affecting myeloma patients. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Erik Low (Chief Executive Myeloma UK) discuss recent changes in the CDF and how they affect myeloma patients.

ASH 2015: We ask Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) what the role of PET/CT is as a measure of MRD post ASCT and ask Professor Antonio Palumbo (University of Torino, Italy) and Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) whether MRD measurement is ready for clinical use

Role of minimal residual disease in treatment tailoring divides experts by Thomas R. Collins Minimal residual disease (MRD) is a guide for tailoring multiple myeloma whose time has… read more.

ASH 2015: Video Interview by Esther Drain. Myeloma XI initial response data at ASH. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) discusses the initial response data from Myeloma XI and whether early intensive therapy is the way forward in managing myeloma, with comment also from Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA).